DK1667708T5 - Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro - Google Patents

Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro

Info

Publication number: DK1667708T5
Authority: DK; Denmark
Prior art keywords: interferon; vitro; beta; polyethylene glycol; increased biological
Prior art date: 2002-12-26

Application number

DK03808554T

Other languages

English (en)

Other versions

DK1667708T3 (da

Inventor

Alexa L Martinez

David L Williams

Mark G P Saifer

Merry R Sherman

Original Assignee

Mountain View Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-26

Filing date

2003-12-23

Publication date

2012-11-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32719161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1667708(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-12-23 Application filed by Mountain View Pharmaceuticals filed Critical Mountain View Pharmaceuticals

2012-09-17 Application granted granted Critical

2012-09-17 Publication of DK1667708T3 publication Critical patent/DK1667708T3/da

2012-11-12 Publication of DK1667708T5 publication Critical patent/DK1667708T5/da

Links

108010005714 Interferon beta-1b Proteins 0.000 title 1
239000002202 Polyethylene glycol Substances 0.000 title 1
238000000338 in vitro Methods 0.000 title 1
229960003161 interferon beta-1b Drugs 0.000 title 1
229920001223 polyethylene glycol Polymers 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/565—IFN-beta

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Virology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

DK03808554T 2002-12-26 2003-12-23 Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro DK1667708T5 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US43602002P	2002-12-26	2002-12-26
US47991303P	2003-06-20	2003-06-20
US47991403P	2003-06-20	2003-06-20
PCT/US2003/041160 WO2004060299A2 (en)	2002-12-26	2003-12-23	Polymer conjugates of interferon-beta with enhanced biological potency

Publications (2)

Publication Number	Publication Date
DK1667708T3 DK1667708T3 (da)	2012-09-17
DK1667708T5 true DK1667708T5 (da)	2012-11-12

Family

ID=32719161

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03808554T DK1667708T5 (da)	2002-12-26	2003-12-23	Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro

Country Status (26)

Country	Link
US (1)	US9125880B2 (da)
EP (1)	EP1667708B9 (da)
JP (2)	JP5207590B2 (da)
KR (1)	KR101238517B1 (da)
CN (1)	CN102319437B (da)
AU (1)	AU2003303635B2 (da)
BR (1)	BR0317742A (da)
CA (1)	CA2511814C (da)
CR (1)	CR7894A (da)
CY (1)	CY1113281T1 (da)
DK (1)	DK1667708T5 (da)
EA (1)	EA008866B1 (da)
EC (1)	ECSP055930A (da)
ES (1)	ES2389183T3 (da)
GE (1)	GEP20084486B (da)
HK (1)	HK1088822A1 (da)
IL (1)	IL169391A (da)
IS (1)	IS7932A (da)
MX (1)	MXPA05006944A (da)
NO (1)	NO339917B1 (da)
NZ (1)	NZ541124A (da)
PL (1)	PL219741B1 (da)
PT (1)	PT1667708E (da)
RS (1)	RS20050502A (da)
TW (1)	TWI406672B (da)
WO (1)	WO2004060299A2 (da)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US7666400B2 (en) *	2005-04-06	2010-02-23	Ibc Pharmaceuticals, Inc.	PEGylation by the dock and lock (DNL) technique
US7173003B2 (en)	2001-10-10	2007-02-06	Neose Technologies, Inc.	Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
KR100964411B1 (ko) *	2002-01-18	2010-06-15	바이오겐 아이덱 엠에이 인코포레이티드	생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜
US8491896B2 (en) *	2002-06-14	2013-07-23	Immunomedics, Inc.	Anti-pancreatic cancer antibodies
AU2003243394B2 (en)	2002-06-07	2008-06-12	Takeda Pharmaceutical Company Limited	Prevention and reduction of blood loss
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
US9599619B2 (en)	2002-06-14	2017-03-21	Immunomedics, Inc.	Anti-pancreatic cancer antibodies
US8821868B2 (en)	2002-06-14	2014-09-02	Immunomedics, Inc.	Anti-pancreatic cancer antibodies
PL396711A1 (pl) *	2002-12-26	2011-12-19	Mountain View Pharmaceuticals, Inc.	Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
BRPI0408358A (pt)	2003-03-14	2006-03-21	Neose Technologies Inc	polìmeros hidrossolúveis ramificados e seus conjugados
WO2004084948A1 (en) *	2003-03-28	2004-10-07	Biopolymed Inc.	Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same
CA2522345A1 (en)	2003-04-09	2004-11-18	Neose Technologies, Inc.	Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en)	2003-04-09	2014-07-29	Novo Nordisk A/S	Glycopegylated factor IX
WO2004100997A2 (en) *	2003-05-12	2004-11-25	Affymax, Inc.	Spacer moiety for poly(ethylene glycol) -modified peptides
NZ543935A (en) *	2003-05-12	2008-06-30	Affymax Inc	Peptides that bind to the erythropoietin receptor
WO2004101600A2 (en) *	2003-05-12	2004-11-25	Affymax, Inc.	Novel poly(ethylene glycol) modified compounds and uses thereof
US9005613B2 (en)	2003-06-16	2015-04-14	Immunomedics, Inc.	Anti-mucin antibodies for early detection and treatment of pancreatic cancer
WO2005012484A2 (en)	2003-07-25	2005-02-10	Neose Technologies, Inc.	Antibody-toxin conjugates
PT1663281E (pt) *	2003-08-29	2014-03-17	Dyax Corp	Inibidores de proteases poli-peguilados
US8633157B2 (en)	2003-11-24	2014-01-21	Novo Nordisk A/S	Glycopegylated erythropoietin
US20080305992A1 (en)	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
US20060040856A1 (en)	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
EP1765853B1 (en)	2004-01-08	2015-10-28	ratiopharm GmbH	O-linked glycosylation of G-CSF peptides
EP1734988A4 (en) *	2004-03-01	2009-08-05	Enzon Pharmaceuticals Inc	INTERFERON BETA-polymer
EP1771066A2 (en)	2004-07-13	2007-04-11	Neose Technologies, Inc.	Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
JP2008507297A (ja) *	2004-07-26	2008-03-13	エンゾンファーマシューティカルズ，インコーポレーテッド	最適化されたインターフェロンβ遺伝子
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
ES2572779T3 (es)	2004-10-29	2016-06-02	Ratiopharm Gmbh	Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF)
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
MX2007005777A (es) *	2004-11-11	2007-07-20	Affymax Inc	Peptidos novedosos que se unen al receptor de eritropoietina.
ES2449195T3 (es)	2005-01-10	2014-03-18	Ratiopharm Gmbh	Factor estimulante de colonias de granulocitos glicopegilado
US8067006B2 (en) *	2005-04-06	2011-11-29	Immunomedics, Inc.	Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US20070154992A1 (en)	2005-04-08	2007-07-05	Neose Technologies, Inc.	Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (ja)	2005-05-25	2013-06-19	ノヴォノルディスクアー／エス	グリコペグ化第ｉｘ因子
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7550433B2 (en)	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
US8883162B2 (en)	2005-10-19	2014-11-11	Ibc Pharmaceuticals, Inc.	Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US9862770B2 (en)	2005-10-19	2018-01-09	Ibc Pharmaceuticals, Inc.	Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US20100226884A1 (en)	2009-01-20	2010-09-09	Immunomedics, Inc.	Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
WO2007056191A2 (en)	2005-11-03	2007-05-18	Neose Technologies, Inc.	Nucleotide sugar purification using membranes
US20080299072A1 (en) *	2005-12-15	2008-12-04	Laboratoires Serono Sa	Chemokine Antagonists
RU2008144426A (ru) *	2006-04-11	2010-05-20	Милеутис Лтд. (Il)	Регулирование репродуктивной эффективности сельскохозяйственных животных
CA2653748A1 (en)	2006-05-02	2007-11-15	Allozyne, Inc.	Non-natural amino acid substituted polypeptides
WO2008011633A2 (en)	2006-07-21	2008-01-24	Neose Technologies, Inc.	Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en)	2006-10-03	2015-03-03	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
JP2010516675A (ja) *	2007-01-17	2010-05-20	イミューノメディクス、インコーポレイテッド	治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分
JP2010523582A (ja)	2007-04-03	2010-07-15	バイオジェネリクスアクチェンゲゼルシャフト	グリコｐｅｇ化ｇ−ｃｓｆを用いた治療方法
MX2009011870A (es) *	2007-05-02	2009-11-12	Ambrx Inc	Polipeptidos de interferon beta modificados y usos de los mismos.
MX2009013259A (es)	2007-06-12	2010-01-25	Novo Nordisk As	Proceso mejorado para la produccion de azucares de nucleotidos.
CA2707840A1 (en)	2007-08-20	2009-02-26	Allozyne, Inc.	Amino acid substituted molecules
CA2696208A1 (en) *	2007-08-21	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
KR20100099298A (ko)	2007-12-20	2010-09-10	메르크 세로노 에스. 에이.	Ｐｅｇ인터페론베타 제형
EP2626079A3 (en)	2008-02-27	2014-03-05	Novo Nordisk A/S	Conjungated factor VIII molecules
US9272029B2 (en)	2009-03-26	2016-03-01	Ibc Pharmaceuticals, Inc.	Interferon lambada-antibody complexes
WO2010023670A2 (en) *	2008-08-28	2010-03-04	Insight Biopharmaceuticals Ltd.	Methods for covalently attaching a polymer to a methionine residue in proteins and peptides
WO2010033240A2 (en) *	2008-09-19	2010-03-25	Nektar Therapeutics	Carbohydrate-based drug delivery polymers and conjugates thereof
US20110171161A1 (en)	2008-09-19	2011-07-14	Nektar Therapeutics	Polymer conjugates of protegrin peptides
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
GB0908393D0 (en) *	2009-05-15	2009-06-24	Almac Sciences Scotland Ltd	Labelling method
DE102009032179A1 (de) *	2009-07-07	2011-01-13	Biogenerix Ag	Verfahren zur Reinigung von Interferon beta
PT3459564T (pt)	2010-01-06	2022-01-31	Takeda Pharmaceuticals Co	Proteínas de ligação à calicreína plasmática
EP2526421B1 (en)	2010-01-22	2018-11-21	Immunomedics, Inc.	Detection of early-stage pancreatic adenocarcinoma
AR080993A1 (es) *	2010-04-02	2012-05-30	Hanmi Holdings Co Ltd	Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
WO2012044684A2 (en) *	2010-10-01	2012-04-05	Biogen Idec Ma Inc.	Interferon-beta for use as monotherapy or in combination with other cancer therapies
KR101309566B1 (ko)	2010-12-10	2013-09-17	포항공과대학교 산학협력단	히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
EP2661450A4 (en)	2011-01-06	2014-04-23	Dyax Corp	PROTEINS BINDING TO PLASMA KALLIKREINE
WO2012112443A2 (en)	2011-02-15	2012-08-23	Immunomedics, Inc.	Anti-mucin antibodies for early detection and treatment of pancreatic cancer
US9446123B2 (en)	2012-06-01	2016-09-20	Ibc Pharmaceuticals, Inc.	Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
US9382329B2 (en)	2012-08-14	2016-07-05	Ibc Pharmaceuticals, Inc.	Disease therapy by inducing immune response to Trop-2 expressing cells
US20150231241A1 (en)	2012-08-14	2015-08-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
US9682143B2 (en)	2012-08-14	2017-06-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
WO2014028560A2 (en)	2012-08-14	2014-02-20	Ibc Pharmaceuticals, Inc.	T-cell redirecting bispecific antibodies for treatment of disease
US9452228B2 (en)	2013-04-01	2016-09-27	Immunomedics, Inc.	Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
WO2015065987A1 (en)	2013-11-01	2015-05-07	Ibc Pharmaceuticals, Inc.	Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
KR102555955B1 (ko)	2014-03-27	2023-07-18	다케다 파머수티컬 컴패니 리미티드	당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
US10988531B2 (en)	2014-09-03	2021-04-27	Immunogen, Inc.	Conjugates comprising cell-binding agents and cytotoxic agents
EP3303370A4 (en)	2015-05-28	2019-03-13	Immunomedics, Inc.	T20-CONSTRUCTS FOR THERAPY AND / OR VACCINES AGAINST HIV (HUMAN IMMUNODEFICIENCY VIRUS)
CN108602893A (zh)	2015-12-11	2018-09-28	戴埃克斯有限公司	血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
JP7472015B2 (ja) *	2017-08-07	2024-04-22	アクロン大学	形状記憶および薬物送達のためのポリ（エステル尿素）
CN109400695B (zh) *	2018-10-31	2020-06-30	中南大学湘雅医院	一种多肽的修饰方法及应用
US20230272001A1 (en) *	2020-05-22	2023-08-31	Merck Sharp & Dohme Llc	Novel processes for preparing conjugates of the il-2 protein
TW202315940A (zh) *	2021-10-13	2023-04-16	芯芮生技開發股份有限公司	幹細胞條件培養基於製備抑制癌症組成物的用途

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
GB1578348A (en)	1976-08-17	1980-11-05	Pharmacia Ab	Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US6610830B1 (en)	1980-07-01	2003-08-26	Hoffman-La Roche Inc.	Microbial production of mature human leukocyte interferons
IT1139487B (it)	1980-09-25	1986-09-24	Genentech Inc	Produzione microbica di interferone di fibroblasti umani
DE3380726D1 (en)	1982-06-24	1989-11-23	Japan Chem Res	Long-acting composition
US4462940A (en)	1982-09-23	1984-07-31	Cetus Corporation	Process for the recovery of human β-interferon-like polypeptides
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
WO1985003934A1 (en)	1984-03-06	1985-09-12	Takeda Chemical Industries, Ltd.	Chemically modified protein and process for its preparation
US4732863A (en)	1984-12-31	1988-03-22	University Of New Mexico	PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
EP0229108B1 (en)	1985-06-26	1990-12-27	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4816440A (en)	1985-09-26	1989-03-28	Cetus Corporation	Stable formulation of biologically active proteins for parenteral injection
US5037969A (en)	1986-07-03	1991-08-06	Takeda Chemical Industries, Ltd.	Glycosyl derivatives and use thereof
US4894330A (en)	1986-12-23	1990-01-16	Cetus Corporation	Purification of recombinant beta-interferon incorporating RP-HPLC
US4961969A (en)	1987-05-11	1990-10-09	Cetus Corporation	Process for recovering microbially produced interferon-β
US5006333A (en)	1987-08-03	1991-04-09	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5080891A (en)	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
IE64284B1 (en)	1987-08-03	1995-07-26	Ddi Pharmaceuticals	Conjugates of superoxide dismutase
US5004605A (en)	1987-12-10	1991-04-02	Cetus Corporation	Low pH pharmaceutical compositions of recombinant β-interferon
US4904584A (en)	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
US4847325A (en)	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
GB8824591D0 (en)	1988-10-20	1988-11-23	Royal Free Hosp School Med	Fractionation process
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US6132763A (en)	1988-10-20	2000-10-17	Polymasc Pharmaceuticals Plc	Liposomes
US5091176A (en)	1988-11-02	1992-02-25	W. R. Grace & Co.-Conn.	Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US4902502A (en)	1989-01-23	1990-02-20	Cetus Corporation	Preparation of a polymer/interleukin-2 conjugate
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en)	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
DE69128944T2 (de)	1990-05-04	1998-06-25	American Cyanamid Co	Stabilisierung von Somatotropin durch Modifizierung von Cysteinsresten
US5219564A (en)	1990-07-06	1993-06-15	Enzon, Inc.	Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
JP3051145B2 (ja)	1990-08-28	2000-06-12	住友製薬株式会社	新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en)	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
WO1992016555A1 (en)	1991-03-18	1992-10-01	Enzon, Inc.	Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en)	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
AU2147192A (en)	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
US5281698A (en)	1991-07-23	1994-01-25	Cetus Oncology Corporation	Preparation of an activated polymer ester for protein conjugation
US5362852A (en)	1991-09-27	1994-11-08	Pfizer Inc.	Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
NZ244778A (en)	1991-10-21	1994-03-25	Ortho Pharma Corp	Peg imidates and protein derivatives thereof
US5221676A (en) *	1992-02-06	1993-06-22	Warner-Lambert Company	7-substituted quinolones and naphthyridones as antibacterial agents
ZA933926B (en)	1992-06-17	1994-01-03	Amgen Inc	Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
CA2101361A1 (en)	1992-08-27	1994-02-28	Robert A. Snow	Low diol polyalkylene oxide biologically active proteinaceous substances
US5581476A (en)	1993-01-28	1996-12-03	Amgen Inc.	Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5395619A (en)	1993-03-03	1995-03-07	Liposome Technology, Inc.	Lipid-polymer conjugates and liposomes
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5919455A (en)	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5605976A (en)	1995-05-15	1997-02-25	Enzon, Inc.	Method of preparing polyalkylene oxide carboxylic acids
DE69430251T2 (de)	1993-11-10	2002-11-07	Enzon, Inc.	Verbesserte interferon-polymerkonjugate
US5951974A (en)	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
US5446090A (en)	1993-11-12	1995-08-29	Shearwater Polymers, Inc.	Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
RO115788B1 (ro)	1994-03-31	2000-06-30	Amgen Inc.	Polipeptidă mgdf, derivat de polipeptidă mgdf, polipeptidă mgdf mono-pegilată şi procedee de obţinere a acestora
DE69533987T2 (de)	1994-05-20	2006-03-16	Hisamitsu Pharmaceutical Co., Inc., Tosu	Protein oder polypeptid, verfahren zur seiner herstellung und entsprechende zwischenprodukte
AU2601895A (en)	1994-05-24	1995-12-18	Amgen Boulder Inc.	Modified insulin-like growth factors
US5730990A (en)	1994-06-24	1998-03-24	Enzon, Inc.	Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en)	1994-09-26	2003-03-20	Kinstler Olaf B.	N-terminally chemically modified protein compositions and methods
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5738846A (en)	1994-11-10	1998-04-14	Enzon, Inc.	Interferon polymer conjugates and process for preparing the same
US5770577A (en)	1994-11-14	1998-06-23	Amgen Inc.	BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5756593A (en)	1995-05-15	1998-05-26	Enzon, Inc.	Method of preparing polyalkyene oxide carboxylic acids
WO1996040731A1 (en)	1995-06-07	1996-12-19	Mount Sinai School Of Medicine Of The City University Of New York	Pegylated modified proteins
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5747639A (en)	1996-03-06	1998-05-05	Amgen Boulder Inc.	Use of hydrophobic interaction chromatography to purify polyethylene glycols
KR20000029673A (ko)	1996-08-02	2000-05-25	오르토-맥네일 파마슈티칼, 인코퍼레이티드	단일의공유결합된ｎ-말단수용성폴리머를갖는폴리펩티드
US5990237A (en)	1997-05-21	1999-11-23	Shearwater Polymers, Inc.	Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
NZ502375A (en)	1997-07-14	2001-11-30	Bolder Biotechnology Inc	The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
US6017876A (en)	1997-08-15	2000-01-25	Amgen Inc.	Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US5985263A (en) *	1997-12-19	1999-11-16	Enzon, Inc.	Substantially pure histidine-linked protein polymer conjugates
US5981709A (en)	1997-12-19	1999-11-09	Enzon, Inc.	α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
DE69921102T2 (de)	1998-03-05	2006-02-02	Chiron Corp., Emeryville	Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
WO1999048948A1 (fr)	1998-03-24	1999-09-30	Nof Corporation	Derives d'oxiranne et leur procede de production
CA2330451A1 (en)	1998-04-28	1999-11-04	Applied Research Systems Ars Holding N.V.	Polyol-ifn-beta conjugates
EP2316467A1 (en)	1998-05-12	2011-05-04	GHC Research Development Corporation	Use of a prolactin variant for treating cancer
US6783965B1 (en)	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2728907C (en)	1998-08-06	2015-11-24	Mountain View Pharmaceuticals, Inc.	Peg-urate oxidase conjugates and use thereof
IL142282A0 (en)	1998-10-16	2002-03-10	Biogen Inc	Compositions containing polymer conjugates of interferon-beta-1a
EP1144613B2 (en)	1999-01-14	2020-05-06	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
PE20010288A1 (es)	1999-07-02	2001-03-07	Hoffmann La Roche	Derivados de eritropoyetina
US7431921B2 (en)	1999-08-27	2008-10-07	Maxygen Aps	Interferon beta-like molecules
US7144574B2 (en)	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
US6531122B1 (en)	1999-08-27	2003-03-11	Maxygen Aps	Interferon-β variants and conjugates
MXPA02001969A (es) *	1999-08-27	2003-07-21	Maxygen Aps	Nuevas moleculas similares a interferon beta.
WO2001048052A1 (fr)	1999-12-24	2001-07-05	Kyowa Hakko Kogyo Co., Ltd.	Glycols de polyalkylene ramifies
ES2290142T3 (es)	2000-05-16	2008-02-16	Bolder Biotechnology, Inc.	Metodos para replegamiento de proteinas que contiene residuos de cisteina libre.
AU2002216749A1 (en)	2000-06-30	2002-01-14	Smithkline Beecham Corporation	Chemokine conjugates
AU2001290312A1 (en)	2000-10-16	2002-04-29	Chugai Seiyaku Kabushiki Kaisha	Peg-modified erythropoietin
ATE505204T1 (de)	2000-12-20	2011-04-15	Hoffmann La Roche	Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
DE60239317D1 (de) *	2001-01-12	2011-04-14	Novartis Vaccines & Diagnostic	Nukleinsäure mukosale immunisierung
ATE432288T1 (de)	2001-02-27	2009-06-15	Maxygen Aps	Neue interferon-beta-ähnliche moleküle
US6887462B2 (en)	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
JP2004522803A (ja)	2001-06-29	2004-07-29	マキシゲン・エイピーエス	インターフェロン製剤
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1461067A1 (en)	2001-12-07	2004-09-29	Intermune, Inc.	Compositions and method for treating hepatitis virus infection
WO2003049699A2 (en)	2001-12-11	2003-06-19	Sun Bio, Inc.	Novel monofunctional polyethylene glycol aldehydes
KR100964411B1 (ko) *	2002-01-18	2010-06-15	바이오겐 아이덱 엠에이 인코포레이티드	생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜
WO2004009774A2 (en)	2002-07-19	2004-01-29	Amgen Inc.	Protein conjugates with a water-soluble biocompatible, biogradable polymer
AU2003254641A1 (en)	2002-08-28	2004-03-19	Maxygen Aps	Interferon beta-like molecules for treatment of cancer
MXPA05002620A (es) *	2002-09-09	2005-05-05	Nektar Therapeutics Al Corp	Alcanales polimericos solubles en agua.
US8129330B2 (en)	2002-09-30	2012-03-06	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) *	2002-09-30	2004-04-01	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1565205A4 (en)	2002-11-18	2006-07-05	Maxygen Inc	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
TWI281864B (en)	2002-11-20	2007-06-01	Pharmacia Corp	N-terminally monopegylated human growth hormone conjugates and process for their preparation
US20040142870A1 (en)	2002-11-20	2004-07-22	Finn Rory F.	N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US8828373B2 (en)	2002-11-20	2014-09-09	Nof Corporation	Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja)	2002-11-20	2010-02-10	日油株式会社	修飾された生体関連物質、その製造方法および中間体
PL396711A1 (pl)	2002-12-26	2011-12-19	Mountain View Pharmaceuticals, Inc.	Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
CA2520875A1 (en)	2003-03-31	2004-10-21	Xencor, Inc.	Methods for rational pegylation of proteins
GB0316294D0 (en)	2003-07-11	2003-08-13	Polytherics Ltd	Conjugated biological molecules and their preparation
EP1734988A4 (en)	2004-03-01	2009-08-05	Enzon Pharmaceuticals Inc	INTERFERON BETA-polymer
RU2298560C2 (ru)	2004-04-30	2007-05-10	Открытое Акционерное Общество "Верофарм"	Конъюгаты белка и производного полиэтиленгликоля, фармацевтическая композиция, способ борьбы с вирусной инфекцией
TWI381850B (zh)	2005-12-30	2013-01-11	Pharmaessentia Corp	藥物與聚合物之共軛物

2003
- 2003-12-23 PL PL379987A patent/PL219741B1/pl unknown
- 2003-12-23 AU AU2003303635A patent/AU2003303635B2/en not_active Ceased
- 2003-12-23 PT PT03808554T patent/PT1667708E/pt unknown
- 2003-12-23 GE GEAP2003008910 patent/GEP20084486B/en unknown
- 2003-12-23 US US10/743,068 patent/US9125880B2/en not_active Expired - Fee Related
- 2003-12-23 CN CN201110224336.2A patent/CN102319437B/zh not_active Expired - Fee Related
- 2003-12-23 ES ES03808554T patent/ES2389183T3/es not_active Expired - Lifetime
- 2003-12-23 TW TW92136583A patent/TWI406672B/zh not_active IP Right Cessation
- 2003-12-23 MX MXPA05006944A patent/MXPA05006944A/es active IP Right Grant
- 2003-12-23 NZ NZ541124A patent/NZ541124A/en not_active IP Right Cessation
- 2003-12-23 JP JP2005508613A patent/JP5207590B2/ja not_active Expired - Fee Related
- 2003-12-23 RS YUP20050502 patent/RS20050502A/sr unknown
- 2003-12-23 KR KR20057012126A patent/KR101238517B1/ko not_active Expired - Fee Related
- 2003-12-23 DK DK03808554T patent/DK1667708T5/da active
- 2003-12-23 BR BR0317742A patent/BR0317742A/pt not_active Application Discontinuation
- 2003-12-23 EA EA200501050A patent/EA008866B1/ru not_active IP Right Cessation
- 2003-12-23 CA CA 2511814 patent/CA2511814C/en not_active Expired - Fee Related
- 2003-12-23 EP EP20030808554 patent/EP1667708B9/en not_active Revoked
- 2003-12-23 WO PCT/US2003/041160 patent/WO2004060299A2/en active Search and Examination
2005
- 2005-06-26 IL IL169391A patent/IL169391A/en active IP Right Grant
- 2005-07-04 IS IS7932A patent/IS7932A/is unknown
- 2005-07-04 CR CR7894A patent/CR7894A/es unknown
- 2005-07-20 NO NO20053556A patent/NO339917B1/no not_active IP Right Cessation
- 2005-07-20 EC ECSP055930 patent/ECSP055930A/es unknown
2006
- 2006-08-21 HK HK06109227A patent/HK1088822A1/xx not_active IP Right Cessation
2012
- 2012-06-20 JP JP2012138434A patent/JP2012232984A/ja not_active Withdrawn
- 2012-09-05 CY CY20121100796T patent/CY1113281T1/el unknown

Also Published As

Publication number	Publication date
PL219741B1 (pl)	2015-07-31
NO20053556D0 (no)	2005-07-20
TW200418507A (en)	2004-10-01
TWI406672B (zh)	2013-09-01
AU2003303635B2 (en)	2009-07-23
NZ541124A (en)	2008-08-29
ECSP055930A (es)	2006-12-20
PL379987A1 (pl)	2006-11-27
CY1113281T1 (el)	2016-04-13
WO2004060299A2 (en)	2004-07-22
US20040126361A1 (en)	2004-07-01
MXPA05006944A (es)	2005-12-14
CR7894A (es)	2006-11-21
HK1088822A1 (en)	2006-11-17
CN102319437B (zh)	2017-10-13
DK1667708T3 (da)	2012-09-17
EP1667708B1 (en)	2012-06-06
GEP20084486B (en)	2008-09-25
JP2012232984A (ja)	2012-11-29
PT1667708E (pt)	2012-09-14
US9125880B2 (en)	2015-09-08
EP1667708A4 (en)	2009-01-14
JP5207590B2 (ja)	2013-06-12
CA2511814A1 (en)	2004-07-22
ES2389183T3 (es)	2012-10-23
NO339917B1 (no)	2017-02-13
NO20053556L (no)	2005-09-23
EA008866B1 (ru)	2007-08-31
EP1667708B9 (en)	2012-10-31
EP1667708A2 (en)	2006-06-14
IS7932A (is)	2005-07-04
IL169391A (en)	2015-09-24
JP2006520323A (ja)	2006-09-07
AU2003303635A1 (en)	2004-07-29
KR20050092022A (ko)	2005-09-16
EA200501050A1 (ru)	2007-02-27
RS20050502A (en)	2007-08-03
KR101238517B1 (ko)	2013-02-28
BR0317742A (pt)	2005-11-22
CA2511814C (en)	2015-02-17
CN102319437A (zh)	2012-01-18
WO2004060299A3 (en)	2006-06-15

Publication	Publication Date	Title
DK1667708T5 (da)	2012-11-12	Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro
PT1196443E (pt)	2004-09-30	Conjugados de eritropoietina com polietileno glicol
IL163006A (en)	2011-01-31	Polyalkylene glycol polymers and conjugates thereof with biologically active compounds
DE60331324D1 (de)	2010-04-01	Polycarbonatharzzusammensetzung und formkörper
DE60335282D1 (de)	2011-01-20	Polycarbonatharzzusammensetzung und formkörper daraus
ATE480567T1 (de)	2010-09-15	Hochkonzentrierter antikörper und proteinformulierungen
DK1687028T3 (da)	2013-01-28	Immunglobulinpræparater med øget stabilitet
DK2433653T3 (da)	2019-08-19	Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
MA29079B1 (fr)	2007-12-03	Fusions et conjugues medicamenteux
BRPI0507118A (pt)	2007-06-19	polipeptìdeos de interferon humano modificado e seus usos
IL165804A0 (en)	2006-01-15	In vitro fertilisation
DE60045790D1 (de)	2011-05-12	Optischer mux/demux
DE60127696D1 (de)	2007-05-16	Graben-dmos-transistor mit schwach-dotierter source-struktur
DK1547639T3 (da)	2013-09-02	Ballonkateter med positioneringslomme
NO20055535D0 (no)	2005-11-23	Makrodkonjugater med anti-inflammatorisk aktivitet
EE05537B1 (et)	2012-04-16	Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks
DE60305582D1 (de)	2006-07-06	Im Stehen leicht anzuziehende Wegwerfwindel
DK1558246T3 (da)	2010-08-09	Prolinderivater med affinitet for calcimkanalens alpha-2-delta subunit
FR2870244B1 (fr)	2011-01-07	Conjugues dipeptidiques antagonistes de l'alpha-msh
DK2112154T3 (da)	2013-10-21	Estre i position 20 af camptothecin
DK1545553T3 (da)	2011-09-12	Anvendelse af alkylphosphocholiner i kombination med antitumormedikamenter
DE502004004912D1 (de)	2007-10-18	Polyethylenglykol und dessen herstellung
SE0203313L (sv)	2004-05-09	Behållare med syrabarriär och användning därav
DE60215849D1 (de)	2006-12-14	Transparentes kautschukmodifiziertes copolymerharz und dieses enthaltende harzzusammensetzung
AU2001217678A1 (en)	2002-05-27	In vitro protein synthesis using glycolytic intermediates as an energy source